ASCO Annual Meeting: Multiple Myeloma | Conference

Philippe Moreau, MD, on Conclusions With VTd Plus Daratumumab in Newly Diagnosed Myeloma at ASCO 2021
July 15, 2021

Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.

Mounzer Agha, MD, Reviews the Safety Profile of Ciltacabtagene Autoleucel in Multiple Myeloma
July 10, 2021

During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.

Philippe Moreau, MD, on Results With Daratumumab Plus VTd in Newly Diagnosed Myeloma at ASCO 2021
July 08, 2021

Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.